Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1988-3-16
|
pubmed:abstractText |
The effect of heparin and of two low molecular weight (low Mr) fractions of heparin on thrombolysis with recombinant human tissue-type plasminogen activator (rt-PA, Genentech Inc., So. San Francisco, CA) or human single chain urokinase-type plasminogen activator (scu-PA, Sandoz AG, Basle, Switzerland) was measured in a rabbit jugular vein thrombosis model. Four bolus injections of 200 anti-Factor Xa units/kg body weight of heparin (Liquemine, Hoffmann-La Roche, Basle, Switzerland), of 90 units/kg of CY 216 (Choay, Paris, France) or of 90 units/kg of CY 222 (Choay, Paris, France) were given intravenously, immediately after the start of the infusion of rt-PA or scu-PA and at hourly intervals during their intravenous infusion over 4 hours. The bolus injections resulted in anti-Factor Xa levels in plasma of 5.7 +/- 1.2 units/ml just before the repeat bolus injections of heparin with corresponding values of 3.9 +/- 0.2 units/ml for CY 216 and 1.6 +/- 0.2 units/ml for CY 222. Thrombolysis with 0.25 mg/kg rt-PA was 36 +/- 1 percent (n = 9) in the absence of anticoagulant, 40 +/- 1 percent (n = 7, p less than 0.05) in the presence of heparin, 49 +/- 5 percent (n = 7, p less than 0.02) with CY 216 and 62 +/- 5 percent (n = 7, p less than 0.01) with CY 222.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolytic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Heparin,
http://linkedlifedata.com/resource/pubmed/chemical/Heparin, Low-Molecular-Weight,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activators,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator,
http://linkedlifedata.com/resource/pubmed/chemical/Urokinase-Type Plasminogen Activator
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0340-6245
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
28
|
pubmed:volume |
58
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
947-50
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:2829381-Animals,
pubmed-meshheading:2829381-Drug Synergism,
pubmed-meshheading:2829381-Drug Therapy, Combination,
pubmed-meshheading:2829381-Fibrinolysis,
pubmed-meshheading:2829381-Fibrinolytic Agents,
pubmed-meshheading:2829381-Heparin,
pubmed-meshheading:2829381-Heparin, Low-Molecular-Weight,
pubmed-meshheading:2829381-Plasminogen Activators,
pubmed-meshheading:2829381-Rabbits,
pubmed-meshheading:2829381-Thrombophlebitis,
pubmed-meshheading:2829381-Tissue Plasminogen Activator,
pubmed-meshheading:2829381-Urokinase-Type Plasminogen Activator
|
pubmed:year |
1987
|
pubmed:articleTitle |
Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
|
pubmed:affiliation |
Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
|
pubmed:publicationType |
Journal Article
|